DG DISPATCH - AAP: DDAVP (Desmopressin Acetate) Effective For Children With Nocturnal Enuresis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - AAP: DDAVP (Desmopressin Acetate) Effective For Children With Nocturnal Enuresis

By Lara Pullen
Special to DG News

CHICAGO, IL -- October 30, 2000 -- DDAVP (desmopressin acetate) is a safe and effective long-term treatment for patients with nocturnal enuresis.

At the American Academy of Pediatrics Annual Meeting, held here this week, Dr. Mark R. Zaontz of the Robert Wood Johnson Medical School in Camden, New Jersey, presented the results of a retrospective review addressing the safety and efficacy of long-term treatment with DDAVP.

Dr. Zaontz and colleagues randomly selected the charts of 114 children with nocturnal enuresis. The parents were interviewed via written questionnaires or telephone to determine the enuretic history of the children. A total of 76 children and families completed the interviews.

Forty-two percent of the families with children on DDAVP reported no wet nights. The patients who were on DDAVP for longer than one year had an average number of 5.7 wet nights per week prior to treatment and 0.6 wet nights per week after treatment. After cessation of DDAVP therapy, 20 percent of the children were 100 percent dry.

Thirty four percent of the children were switched from nasal to oral treatment, with the majority (64 percent) experiencing no change in the number of wet nights. Oral therapy did result in an improvement, however, for 30 percent of the children.

Overall, the investigators found that 61 percent of the families reported either an excellent or very good response on DDAVP and their children remained on treatment for up to seven years. In addition, they found that oral DDAVP appeared to result in improved dryness when compared with the nasal spray.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities